These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. Musiek ES; Gomez-Isla T; Holtzman DM J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585 [No Abstract] [Full Text] [Related]
5. Revisiting FDA Approval of Aducanumab. Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282 [No Abstract] [Full Text] [Related]
6. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? Planche V; Villain N JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750 [No Abstract] [Full Text] [Related]
7. What the Aducanumab Approval Reveals About Alzheimer Disease Research. Manly JJ; Glymour MM JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885 [No Abstract] [Full Text] [Related]
8. Aducanumab: First Approval. Dhillon S Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167 [TBL] [Abstract][Full Text] [Related]
9. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related]
10. Aducanumab for Alzheimer's disease: A regulatory perspective. Nisticò R; Borg JJ Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830 [TBL] [Abstract][Full Text] [Related]
11. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. Rabinovici GD N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284 [No Abstract] [Full Text] [Related]
12. Accelerated Approval of Aducanumab: Where Do We Stand Now? Barenholtz Levy H Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939 [TBL] [Abstract][Full Text] [Related]
13. Aducanumab and the Business of Alzheimer Disease-Some Choice. Karlawish J JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302 [No Abstract] [Full Text] [Related]
14. The Problem of Aducanumab for the Treatment of Alzheimer Disease. Alexander GC; Karlawish J Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642 [No Abstract] [Full Text] [Related]
15. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies. Yuksel JM; Noviasky J; Britton S Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846 [No Abstract] [Full Text] [Related]
16. ENGAGE and EMERGE: Truth and consequences? Kuller LH; Lopez OL Alzheimers Dement; 2021 Apr; 17(4):692-695. PubMed ID: 33656288 [TBL] [Abstract][Full Text] [Related]
17. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab. Emanuel EJ JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184 [No Abstract] [Full Text] [Related]
18. Aducanumab and the FDA - where are we now? Fillit H; Green A Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064 [No Abstract] [Full Text] [Related]
19. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Mukhopadhyay S; Banerjee D J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359 [TBL] [Abstract][Full Text] [Related]
20. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? Schulman KA; Greicius MD; Richman B JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572 [No Abstract] [Full Text] [Related] [Next] [New Search]